Literature DB >> 6312793

Cystic dilatation as a radiographic sign of cholangiocarcinoma complicating sclerosing cholangitis.

L E Gluskin, J A Payne.   

Abstract

A 40-year-old woman with ulcerative colitis and sclerosing cholangitis developed jaundice unresponsive to steroids. Endoscopic retrograde cholangiopancreatography showed multiple cystic dilatations similar in appearance to a previous report of a patient with sclerosing cholangitis who had an associated cholangiocarcinoma. Subsequent laparotomy led to the diagnosis of a cholangiocarcinoma. We conclude that the presence of cystic dilatation on cholangiography in patients with sclerosing cholangitis is highly suggestive of an associated cholangiocarcinoma.

Entities:  

Mesh:

Year:  1983        PMID: 6312793

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

Review 1.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis.

Authors:  Laetitia Nguyen; Nora Cazzagon; Christophe Corpechot; Sanaâ El Mouhadi; Sara Lemoinne; Olivier Chazouillères; Lionel Arrivé
Journal:  Eur Radiol       Date:  2018-08-29       Impact factor: 5.315

3.  The role of endoscopic retrograde cholangiopancreatography in preoperative assessment of bile duct cancer.

Authors:  M Tanaka; Y Ogawa; S Matsumoto; F Nakayama
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

Review 4.  Bile duct carcinoma in patients with ulcerative colitis. Relationship to sclerosing cholangitis: report of six cases and review of the literature.

Authors:  S H Mir-Madjlessi; R G Farmer; M V Sivak
Journal:  Dig Dis Sci       Date:  1987-02       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.